AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by analysts at Deutsche Bank AG in a report issued on Wednesday. They presently have a GBX 5,800 ($75.71) target price on the biopharmaceutical company’s stock. Deutsche Bank AG’s price objective points to a potential upside of 15.40% from the stock’s current price.
AZN has been the topic of a number of other research reports. Jefferies Group reissued a “hold” rating on shares of AstraZeneca plc in a report on Monday, June 6th. Berenberg Bank set a GBX 5,550 ($72.44) price objective on shares of AstraZeneca plc and gave the stock a “buy” rating in a report on Thursday, August 25th. HSBC reissued a “hold” rating and set a GBX 4,240 ($55.35) price objective on shares of AstraZeneca plc in a report on Friday, June 17th. Citigroup Inc. reaffirmed a “buy” rating on shares of AstraZeneca plc in a report on Wednesday, July 27th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) target price on shares of AstraZeneca plc and gave the company a “sell” rating in a report on Wednesday, August 10th. Five equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. AstraZeneca plc currently has an average rating of “Hold” and an average target price of GBX 4,926.80 ($64.31).
Shares of AstraZeneca plc (LON:AZN) opened at 4969.00 on Wednesday. The company’s market capitalization is GBX 62.86 billion. The stock has a 50 day moving average of GBX 5,019.33 and a 200-day moving average of GBX 4,394.52. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00.
The business also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were issued a GBX 68.70 ($0.90) dividend. This represents a yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 11th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.